Noviti Pharma has gained regulatory approval for the ANDA220597 drug, a milestone that establishes a new proprietary pathway into the market and positions the company to capitalize on significant commercial opportunities. This clearance removes a major regulatory hurdle and provides the pharma firm with potential revenue and investor visibility leading up to the September launch.